GENETIKA
26.7.2022 08:02:06 CEST | Business Wire | Press release
Genetika+, a company developing personalized medicine solutions to optimize treatment for psychiatric and neurological diseases, announced today an award of up to €17.5 million of grant funding combined with equity investment to bring NeuroKaire to market. This represents the maximum possible grant from the European Commission and will be used for the company’s precision medicine tool for optimizing drug choice to treat major depressive disorder (MDD). The award was granted through the European Commission’s European Innovation Council (EIC) Accelerator for Europe’s high potential start-ups. Genetika+’s proposal was selected from over 1000 start-ups and SMEs.
“We are excited by this important vote of confidence from the European Commission’s Innovation Council,” said Talia Cohen Solal, co-founder and CEO of Genetika+. “This funding is a validation of our work to date and will accelerate our bringing this much needed tool to market, enabling providers to effectively match the right therapy to their patient's unique needs."
MDD affects 300 million people globally and can reduce an individual’s lifespan by as much as 14 years. A physician must choose from over 70 different medications and combinations when selecting a drug for a patient with MDD. Each drug takes 4 - 6 weeks to test, causing the patient to lose months to years of their lives to disability and suffering, including risk of suicide during the process of searching for the right treatment. Up to 63% of people suffering from depression do not receive adequate treatment due to the heterogeneity of the disease, uniquely affecting each individual. Response to treatment varies significantly. This trial-and-error process impacts patients’ lives, physicians time and payers and governments budgets. Precision mental health treatment is urgently needed.
The EIC funding will go toward further clinical validation of the platform, with several clinical studies underway and additional ones planned. It will also support platform scale-up to enable large scale clinical use.
About Genetika+
Genetika+, founded in 2018 by Talia Cohen-Solal, Ph.D., and Daphna Laifenfeld, Ph.D., is developing personalized medicine solutions to optimize treatment for psychiatric and neurological diseases. The company’s Brain-in-a-Dish technology helps physicians find the best treatment for their patients. In its first indication, depression, Genetika+ uses patented technology to rapidly test more than 70 approved antidepressants and drug combinations against an individual patient’s unique neurological biomarkers. Combined with patients’ genetic and medical history, Genetika+ can predict the optimal drug or combination therapy for each patient. This opens the door to faster treatment, fewer side effects, and lower dosing, and the elimination of arduous trial-and-error treatment protocols and needless loss of life. To learn more, follow us on LinkedIn
or on Twitter @Genetikaplus.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220725005850/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ennov Announces Strategic Growth Investment from Bregal Sagemount and Ardian20.5.2026 14:00:00 CEST | Press release
Ennov (the “Company”), a global provider of end-to-end regulatory, quality, and clinical software solutions for life sciences and healthcare companies, today announced a strategic growth investment led by Bregal Sagemount (“Sagemount”), a leading growth-focused private equity firm, with participation from Ardian, a global private investment firm. The investment will support the Company’s continued expansion, with a focus on AI innovation, global go-to-market acceleration, and scaling its product offering. Founded and headquartered in Paris, Ennov provides a unified compliance platform that serves as a centralized system of record for global life sciences organizations. The platform supports the management of content and data across key domains, including Regulatory, Quality, Commercial, Clinical, and Pharmacovigilance. Its integrated architecture and unified data model enable faster deployment, improved user adoption, consistent compliance, and AI-driven efficiency across global operat
TreviPay Research Tracks the Evolution of B2B Buyer Expectations as AI Reshapes the Purchasing Process20.5.2026 14:00:00 CEST | Press release
New global study finds 73% of B2B buyers use AI in purchasing workflows while demand for invoice terms and consistent payment experiences reaches a three-year high New research from TreviPay, a global B2B payments infrastructure partner, found 88% of B2B buyers report high loyalty to their suppliers, consistent with TreviPay’s 2023 research. In 2026, buyers now place greater decision power on how efficiently and consistently suppliers deliver across the purchasing, payment and invoicing experience, meaning their loyalty is dependent on how well a supplier can execute. TreviPay’s latest report, The Evolution of the B2B Buyer, builds on the company’s 2023 B2B buyer research and examines how expectations have evolved across payments, onboarding, invoice terms, automation and supplier relationships. Key findings include:AI integration and digital maturity are reshaping purchasing. Seventy-three percent of buyers now use AI in purchasing workflows, showing automation has moved from explorat
Thales Announces Strategic Partnership with Google Cloud to Launch a New Sovereign Cloud in Germany20.5.2026 13:54:00 CEST | Press release
Thales and Google Cloud have signed a landmark partnership to launch a new European sovereign cloud offering in Germany, delivering advanced cloud capabilities to customers while keeping their data confidential, secure and fully sovereign. This solution will live on dedicated infrastructure that will be managed and operated by a new German entity, which Thales will fully own and control. This offering is designed to meet the stringent digital sovereignty and regulatory requirements of German public sector organizations and highly regulated industries, and meet Germany's new C3A framework criteria. It is available in Preview now and aims for General Availability by the end of 2026. By establishing this new sovereign region alongside PREMI3NS by S3NS, a Thales subsidiary, this new partnership marks an industry-first: a pan-European, geo-redundant, sovereign cloud offering that delivers a unique cross-border disaster recovery solution in Europe for Europe. Thales, a global leader in high
Klarna launches AI-powered Shopping Search app in ChatGPT20.5.2026 13:30:00 CEST | Press release
Klarna, the global digital bank and flexible payments provider, today launched the Klarna Shopping Search app in ChatGPT, bringing real-time product discovery directly into the conversation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260520024278/en/ The Klarna Shopping Search app is live in ChatGPT The launch comes as AI-powered product search reshapes online retail: during the 2025 holiday season, traffic from AI platforms to retail sites grew nearly 700%, with those shoppers converting at 31% higher rates. Until now, consumers asking AI models for shopping help have had to open new browser tabs, navigate competing sites, and reconcile outdated prices. With the Klarna Shopping Search app in ChatGPT, they simply describe what they're looking for and instantly see visual results with up-to-date prices, availability, and offers from multiple merchants, all within the same conversation. The Klarna Shopping Search app then
IAMPHENOM Europe 2026 Registration Opens: HR’s Leading Conference for Agentic AI Learning Returns20.5.2026 13:00:00 CEST | Press release
Europe’s CHROs, CIOs and HRIT Leaders Head to Paris for Learning How AI Redesigns Work Operations Across Hiring, Development and Retention Phenom, the leader in applied AI with an infrastructure built specifically to redesign work operations, today announced registration is open for IAMPHENOM Europe 2026, taking place 4-5 November in Paris, France. The only applied AI event dedicated to human resources on the continent, IAMPHENOM Europe gives HR and HRIT leaders the agentic AI strategies, instruction and proof points they need to build their AI-augmented workforce to address their biggest hiring, development and retention challenges. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260520683492/en/ Phenom today announced registration is open for IAMPHENOM Europe 2026. The only applied AI event dedicated to human resources on the continent is taking place 4-5 November in Paris, France. European organisations face pressure from
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom